Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System

Magdi Elsallab1,2, Moataz Ellithi3, Matthew A Lunning3

  • 1Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, MA.

Blood
|March 14, 2024
PubMed

Related Concept Videos